American Society of Hematology

Fig. 2.

$Fig. 2. Effect of PKC-ɛ inhibitory peptide on the growth of erythroid (BFU-E) and granulo-macrophagic (CFU-GM) colonies (A) and the translocation of PKC-ɛ to the membrane fraction (B). In (A), data are expressed as the means ± SD of three separate experiments performed in triplicate. A statistically significant (*P < .01) increase in the number of BFU-E was noticed in the presence of the PKC-ɛ inhibitory peptide. In (B), Western blot analysis of PKC-ɛ in the fractionated lysates of untreated and IL-3–treated 32D cells cultured in the presence or absence of PKC-ɛ inhibitory peptide or control peptide. S, soluble fractions. M, membrane fractions.$

Effect of PKC-ɛ inhibitory peptide on the growth of erythroid (BFU-E) and granulo-macrophagic (CFU-GM) colonies (A) and the translocation of PKC-ɛ to the membrane fraction (B). In (A), data are expressed as the means ± SD of three separate experiments performed in triplicate. A statistically significant (*P < .01) increase in the number of BFU-E was noticed in the presence of the PKC-ɛ inhibitory peptide. In (B), Western blot analysis of PKC-ɛ in the fractionated lysates of untreated and IL-3–treated 32D cells cultured in the presence or absence of PKC-ɛ inhibitory peptide or control peptide. S, soluble fractions. M, membrane fractions.

This Feature Is Available To Subscribers Only